Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,156,882
  • Shares Outstanding, K 394,939
  • Annual Sales, $ 1,944 M
  • Annual Income, $ -2,822 M
  • EBIT $ -3,074 M
  • EBITDA $ -2,926 M
  • 60-Month Beta 1.32
  • Price/Sales 10.88
  • Price/Cash Flow N/A
  • Price/Book 2.45

Options Overview Details

View History
  • Implied Volatility 78.03% (+3.88%)
  • Historical Volatility 69.16%
  • IV Percentile 74%
  • IV Rank 47.51%
  • IV High 104.55% on 04/08/25
  • IV Low 54.03% on 08/06/25
  • Expected Move (DTE 5) 3.62 (6.76%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 99,058
  • Volume Avg (30-Day) 74,523
  • Put/Call OI Ratio 1.02
  • Today's Open Interest 968,665
  • Open Int (30-Day) 982,697
  • Expected Range 49.95 to 57.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -2.03
  • Number of Estimates 9
  • High Estimate -1.65
  • Low Estimate -2.43
  • Prior Year -2.52
  • Growth Rate Est. (year over year) +19.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.65 +46.15%
on 02/11/26
54.02 -0.83%
on 02/23/26
+8.12 (+17.87%)
since 01/27/26
3-Month
23.92 +123.95%
on 12/02/25
55.20 -2.95%
on 01/22/26
+28.56 (+114.19%)
since 11/26/25
52-Week
22.28 +140.44%
on 11/21/25
55.20 -2.95%
on 01/22/26
+22.48 (+72.31%)
since 02/27/25

Most Recent Stories

More News
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19

mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positive CHMP...

MRNA : 53.57 (+3.60%)
FDA to offer bonus payments to staffers who complete speedy drug reviews

The head of the Food and Drug Administration plans to start offering bonus payments to agency drug reviewers who complete their work ahead of the schedule

MRNA : 53.57 (+3.60%)
A children's hospital is renamed for Dolly Parton and hopes to transform pediatric care in Tennessee

The East Tennessee Children's Hospital is now known as Dolly Parton Children's Hospital

$SPX : 6,878.88 (-0.43%)
$DOWI : 48,977.92 (-1.05%)
MRNA : 53.57 (+3.60%)
$IUXX : 24,960.04 (-0.30%)
3 Reasons to Avoid MRNA and 1 Stock to Buy Instead

3 Reasons to Avoid MRNA and 1 Stock to Buy Instead

MRNA : 53.57 (+3.60%)
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc.  (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic...

TECX : 23.45 (-2.01%)
MRNA : 53.57 (+3.60%)
Moderna’s Q4 Earnings Call: Our Top 5 Analyst Questions

Moderna’s Q4 Earnings Call: Our Top 5 Analyst Questions

MRNA : 53.57 (+3.60%)
US stocks slip as AI fears keep rumbling and oil prices climb

U.S. stocks fell, while oil prices climbed

APO : 104.60 (-8.57%)
META : 648.18 (-1.34%)
NVDA : 177.19 (-4.16%)
ARES : 112.01 (-5.14%)
OWL : 10.55 (-5.97%)
$SPX : 6,878.88 (-0.43%)
$IUXX : 24,960.04 (-0.30%)
ETSY : 54.88 (-0.54%)
EBAY : 90.86 (+3.37%)
CVNA : 334.16 (-5.58%)
$DOWI : 48,977.92 (-1.05%)
MRNA : 53.57 (+3.60%)
Moderna to Present at Upcoming Conferences in March 2026

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 19, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:

MRNA : 53.57 (+3.60%)
FDA will drop two-study requirement for new drug approvals, aiming to speed access

The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies for new drug approvals

$SPX : 6,878.88 (-0.43%)
$DOWI : 48,977.92 (-1.05%)
MRNA : 53.57 (+3.60%)
$IUXX : 24,960.04 (-0.30%)
Nvidia leads the US stock market higher

The U.S. stock market ticked higher, led by its most influential stock, Nvidia

NFLX : 96.24 (+13.77%)
NVDA : 177.19 (-4.16%)
META : 648.18 (-1.34%)
BAC : 49.83 (-4.72%)
$SPX : 6,878.88 (-0.43%)
ADI : 355.79 (+0.41%)
$IUXX : 24,960.04 (-0.30%)
GIS : 45.23 (+0.67%)
PSKY : 13.51 (+20.84%)
CDNS : 301.40 (+1.28%)
$DOWI : 48,977.92 (-1.05%)
MRNA : 53.57 (+3.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 57.44
2nd Resistance Point 55.53
1st Resistance Point 54.55
Last Price 53.57
1st Support Level 51.66
2nd Support Level 49.75
3rd Support Level 48.77

See More

52-Week High 55.20
Last Price 53.57
Fibonacci 61.8% 42.62
Fibonacci 50% 38.74
Fibonacci 38.2% 34.86
52-Week Low 22.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar